Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström’s macroglobulinemia

References

• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937–951.
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113:4163–4170.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:116–120.
   PubMed Web of Science ®Google Scholar
• Tamburini J, Levy V, Chaleteix C, et al. Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients. Leukemia 2005;19:1831–1834.
   PubMed Web of Science ®Google Scholar
• Laurencet FM, Zulian GB, Guetty-Alberto M, et al. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 1999;79:1215–1219.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Louviaux I, Michaux JL, et al. Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin’s lymphoma. Leukemia 2000;14:1136–1142.
   PubMed Web of Science ®Google Scholar
• Treon SP, Agus TB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macroglobulinemia. J Immunother 2001;24:272–279.
   Web of Science ®Google Scholar
• Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317–324.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327–2333.
   PubMed Web of Science ®Google Scholar
• Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximabtherapy in Waldenstrom's macroglobulinemia. Ann Oncol 2005;16:132–138.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047–2055.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2009;113:3673–3678.
   PubMed Web of Science ®Google Scholar
• Tam CS, Wolf M, Prince HM, et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006;106:2412–2420.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009;23:153–161.
   PubMed Web of Science ®Google Scholar
• Hensel M, Villalobos M, Kornacker M, et al. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 2005;6:131–135.
   PubMedGoogle Scholar
• Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013;160:171–176.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, von Grunhagen U, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line-treatment in patients with indolent lymphomas and Waldenström’s macroglobulinemia [abstract]. Presented at The Sixth International Workshop on Waldenström's Macroglobulinemia, 6–10 October 2010, Venice, Italy.
   Google Scholar
• Yared J, Kimball A, Baer MR, et al. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk 2013;13:253–257.
   PubMed Web of Science ®Google Scholar
• Ho AD, Hensel M. Pentostatin and purine analogs for indolent lymphoid malignancies. Future Oncol 2006;2:169–183.
   PubMedGoogle Scholar
• Kay NE, Wu W, Kabat B, et al. Pentostatin and rituximab therapy for previously untreated BCLL. Cancer 2010;116:2180–2187.
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatine, cyclophosphamide, and rituximab shows significant clinical activity without accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109:405–411.
   PubMed Web of Science ®Google Scholar
• Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:1575–1581.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559–3566.
   PubMed Web of Science ®Google Scholar
• Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2013;31:2103–2109.
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenström's macroglobulinemia. Clin Cancer Res 2009;15:355–360.
   PubMed Web of Science ®Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. J Clin Oncol 2009;27:3830–3835.
   PubMed Web of Science ®Google Scholar
• Chen C, Kouroukis CT, White D, et al. Bortezomib in relapsed or refractory Waldenström’s macroglobulinemia. Clin Lymph Myeloma 2009;9:74–76.
   PubMedGoogle Scholar
• Ghobrial IM, Moreau P, Harris B, et al. A multicenter phase II study of single-agent enzastaurin in previously treated waldenstrom macroglobulinemia. Clin Cancer Res 2012;18:5043–5050.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28:1408–1414.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010;16:1033–1041.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Yang G, et al. A prospective multicenter study of the Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Blood 2013;122(Suppl. 1): Abstract 251.
   Google Scholar